Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announced the appointments of Mark Gaffney as Chief Executive Officer and Mark Altmeyer as Chair of the Board.
Gene Therapy Promising for Rare Jaundice Syndrome
Gene therapy for Crigler-Najjar syndrome appeared promising in patients treated at a higher dose, a phase I/II trial showed. A single infusion of GNT0003 —
August 17, 2023